CR Double-Crane Pharmaceutical's Unit Gets Nod to Market Pregabalin API

MT Newswires Live

04/14

China Resources Double-Crane Pharmaceutical's (SHA:600062) unit, Double-Crane Pharmaceutical (Shangqiu), obtained approval from the Chinese drug administration to market a chemical active ingredient for pregabalin, according to a Shanghai Stock Exchange filing on Saturday.

Pregabalin is a medication used to treat postherpetic neuralgia and fibromyalgia.

The company invested 8.4 million yuan into the research and development of the active pharmaceutical ingredient or API, the filing said.

The company's shares rose over 1% in recent trade.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2527792395"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2527792395\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2527792395?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-04-14 11:13","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2527792395","market":"sg","top_or_hot":-1,"title":"CR Double-Crane Pharmaceutical's Unit Gets Nod to Market Pregabalin API","media":"MT Newswires Live","content":"<html><body><p> China Resources Double-Crane Pharmaceutical's (SHA:600062) unit, Double-Crane Pharmaceutical (Shangqiu), obtained approval from the Chinese drug administration to market a chemical active ingredient for pregabalin, according to a Shanghai Stock Exchange filing on Saturday.</p><p>Pregabalin is a medication used to treat postherpetic neuralgia and fibromyalgia.</p><p>The company invested 8.4 million yuan into the research and development of the active pharmaceutical ingredient or API, the filing said.</p><p>The company's shares rose over 1% in recent trade.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CR Double-Crane Pharmaceutical's Unit Gets Nod to Market Pregabalin API</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCR Double-Crane Pharmaceutical's Unit Gets Nod to Market Pregabalin API\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-04-14 11:13</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> China Resources Double-Crane Pharmaceutical's (SHA:600062) unit, Double-Crane Pharmaceutical (Shangqiu), obtained approval from the Chinese drug administration to market a chemical active ingredient for pregabalin, according to a Shanghai Stock Exchange filing on Saturday.</p><p>Pregabalin is a medication used to treat postherpetic neuralgia and fibromyalgia.</p><p>The company invested 8.4 million yuan into the research and development of the active pharmaceutical ingredient or API, the filing said.</p><p>The company's shares rose over 1% in recent trade.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"600062","symbol_name":"华润双鹤","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2527792395","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2527792395","pubTimestamp":1744600403,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"China Resources Double-Crane Pharmaceutical's (SHA:600062) unit, Double-Crane Pharmaceutical (Shangqiu), obtained approval from the Chinese drug administration to market a chemical active ingredient f","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"600062":"华润双鹤","BK0188":"融资融券","BK0185":"二线龙头","BK0175":"白马股","BK0010":"央企","OTX.SI":"迈怡汇有限公司","BK0028":"国家队","BK0239":"医药制造"},"translate_title":"华润双鹤药业子公司获准上市普瑞巴林原料药","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"600062":0.9,"OTX.SI":1},"content_text":"China Resources Double-Crane Pharmaceutical's (SHA:600062) unit, Double-Crane Pharmaceutical (Shangqiu), obtained approval from the Chinese drug administration to market a chemical active ingredient for pregabalin, according to a Shanghai Stock Exchange filing on Saturday.Pregabalin is a medication used to treat postherpetic neuralgia and fibromyalgia.The company invested 8.4 million yuan into the research and development of the active pharmaceutical ingredient or API, the filing said.The company's shares rose over 1% in recent trade.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}